Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Margherita Turinetto"'
Autor:
Laetitia Collet, Brunhilde Hanvic, Margherita Turinetto, Isabelle Treilleux, Nicolas Chopin, Olivia Le Saux, Isabelle Ray-Coquard
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BRCA1/2 genes are part of homologous recombination (HR) DNA repair pathways in charge of error-free double-strand break (DSB) repair. Loss-of-function mutations of BRCA1/2 genes have been associated for a long time with breast and ovarian cancer here
Externí odkaz:
https://doaj.org/article/4ce29ee231a040ebb2aded80b23eceb5
Autor:
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, Giulia Scotto, Valentina Tuninetti, Margherita Turinetto, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Vera Loizzi, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Publikováno v:
Frontiers in Oncology, Vol 13 (2024)
Externí odkaz:
https://doaj.org/article/dcf619c78545464a823c5d3ef4cc8cc3
Autor:
Francesca Arezzo, Gaia Giannone, Daniele Castaldo, Giulia Scotto, Valentina Tuninetti, Margherita Turinetto, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Vera Loizzi, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionEndometrial cancer (EC) represents 3.4% of all newly diagnosed cancer cases and is responsible for 2.1% of all cancer-related deaths. Approximately 10%–15% of women with EC are diagnosed with advanced-stage disease, resulting in a repor
Externí odkaz:
https://doaj.org/article/f5bb38ac79f64befb91e18a43fc5f3ed
Autor:
Margherita Turinetto, Andrea Ricotti, Claudia Marchetti, Carmela Pisano, Claudio Zamagni, Chiara Cassani, Paola Malaguti, Alessandra Baldoni, Paolo Scollo, Giuseppa Scandurra, Alessandro Parisi, Grazia Artioli, Innocenza Palaia, Laura Vertechy, Alice Bergamini, Elisa Picardo, Valentina Tuninetti, Giulia Scotto, Giovanni Scambia, Sandro Pignata, Giorgio Valabrega
Publikováno v:
Cancers, Vol 16, Iss 1, p 41 (2023)
Objective: While PLD-Trabectedin is an approved treatment for relapsed platinum-sensitive ovarian cancer, its efficacy and tolerability has so far not been tested extensively in patients who progress after poly ADP-ribose polymerase inhibitor (PARPi)
Externí odkaz:
https://doaj.org/article/477121fd5265443fb6698f7080276f56
Autor:
Valentina Tuninetti, Luca Pace, Eleonora Ghisoni, Virginia Quarà, Francesca Arezzo, Andrea Palicelli, Vincenzo Dario Mandato, Elena Geuna, Gennaro Cormio, Nicoletta Biglia, Lucia Borsotti, Silvia Gallo, Annamaria Ferrero, Elena Jacomuzzi, Luca Fuso, Jeremy Oscar Smith Pezua Sanjinez, Andrea Puppo, Andrea Caglio, Chiara Rognone, Margherita Turinetto, Giulia Scotto, Massimo Di Maio, Giorgio Valabrega
Publikováno v:
Cancers, Vol 15, Iss 14, p 3639 (2023)
Background: There is poor evidence regarding sensitivity to chemotherapy in endometrial cancer (EC) based on microsatellite instability (MSI)/mismatch repair (MMR) status. Methodology: The RAME study is a retrospective analysis aiming to assess respo
Externí odkaz:
https://doaj.org/article/6ab86d5ec9294299a5042250464490b6
Autor:
Gaia Giannone, Daniele Castaldo, Valentina Tuninetti, Giulia Scotto, Margherita Turinetto, Anna Amela Valsecchi, Michele Bartoletti, Serafina Mammoliti, Grazia Artioli, Giorgia Mangili, Vanda Salutari, Domenica Lorusso, Gennaro Cormio, Claudio Zamagni, Antonella Savarese, Massimo Di Maio, Graziana Ronzino, Carmela Pisano, Sandro Pignata, Giorgio Valabrega
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundEndometrial cancer (EC) therapeutic and diagnostic approaches have been changed by the development of a new prognostic molecular classification, the introduction of dostarlimab in microsatellite instability (MSI) high pre-treated advanced E
Externí odkaz:
https://doaj.org/article/b9a686d498904e73bedff9d6707f8bb3
Autor:
Valentina Tuninetti, Eleonora Ghisoni, Sandro Pignata, Elisa Picardo, Francesco Raspagliesi, Claudia Andreetta, Elena Maldi, Grazia Artioli, Serafina Mammoliti, Lucia Zanchi, Angelica Sikokis, Nicoletta Biglia, Alessandro Parisi, Vincenzo Dario Mandato, Claudia Carella, Gennaro Cormio, Marco Marinaccio, Andrea Puppo, Biagio Paolini, Lucia Borsotti, Giulia Scotto, Margherita Turinetto, Dario Sangiolo, Massimo Di Maio, Giorgio Valabrega
Publikováno v:
Cancers, Vol 15, Iss 4, p 1032 (2023)
Background: There is compelling need for novel biomarkers to predict response to PARP inhibitors (PARPi) in BRCA wild-type (WT) ovarian cancer (OC). Methods: MITO 37 is a multicenter retrospective study aiming at correlating Ki67 expression at diagno
Externí odkaz:
https://doaj.org/article/6f3569dc15f5475d9beb727c4b8256ce
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
PARP inhibitors (PARPi) have shown promising clinical results and have revolutionized the landscape of ovarian cancer management in the last few years. While the core mechanism of action of these drugs has been largely analyzed, the interaction betwe
Externí odkaz:
https://doaj.org/article/9264d7dddfec4ddbbc8c7bcda7f8e398
Autor:
Margherita Turinetto, Anna A. Valsecchi, Valentina Tuninetti, Giulia Scotto, Fulvio Borella, Giorgio Valabrega
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 7, p 3559 (2022)
The prognosis of invasive cervical cancer (CC) remains poor, with a treatment approach that has remained the same for several decades. Lately, a better understanding of the interactions between the disease and the host immune system has allowed resea
Externí odkaz:
https://doaj.org/article/4ebaa6792bcc493aa7e7d93e602b442b
Autor:
Giulia Scotto, Fulvio Borella, Margherita Turinetto, Valentina Tuninetti, Anna A. Valsecchi, Gaia Giannone, Stefano Cosma, Chiara Benedetto, Giorgio Valabrega
Publikováno v:
Cells, Vol 10, Iss 12, p 3408 (2021)
Epithelial ovarian cancer (EOC) is the leading cause of death among women affected by gynaecological malignancies. Most patients show advanced disease at diagnosis (FIGO stage III-IV) and, despite the introduction of new therapeutic options, most wom
Externí odkaz:
https://doaj.org/article/04c36cfa31eb4488a102ff18696d6e77